| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
BLA Submission example | BLA | — | Subscribe to access the data. | Nanomedicine | Dermatologic System | ||
BLA Submission example | BLA | — | Subscribe to access the data. | Nanomedicine | Dermatologic System | ||
BLA Submission example | BLA | — | Subscribe to access the data. | Nanomedicine | Dermatologic System |
Recent Updates
Recently added Catalysts
MoonLake Immunotherapeutics$19.88
+0.86 (+4.52%)
C 44Pipeline Score Overvalued Pharma · Clinical
Market Cap
1.34 B
EPS
-3.87
P/E Ratio
-
Value Trade
10.42 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
54.52 M
Operating CF
-66.29 M
Total Assets
400.37 M
Total Liabilities
146.35 M
Equity
254.02 M
D/E Ratio
12,345
-0.38 %
Week
4.12 %
1 Month
1.17 %
3 Month
39.92 %
6 Month
82.81 %
5 Year
79.04 %
All Time
Cash Data
Cash Position
357.92 M
Monthly Burn
22.09 M
Runway
13.6 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
879.41 K
52 Week Range
5.95 - 62.75
% held by Insiders
13.44 %
% held by Institutions
73.65 %
Enterprise Value
1.08 B
Total Shares
73.63 M
Short %
10.32 %
Float Shares
61.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for MoonLake Immunotherapeutics
141Total events
8Upcoming
63Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 2
TBD
T1BLA Submission
Subscribe to view catalyst details
TBD
T1PDUFA Date
Subscribe to view catalyst details
Event history 2
TBD
◆BLA SubmissionSLKFiledRegulatory Filing
Subscribe to view catalyst details
TBD
●Trial InitiationSonelokimabFiledTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | sonelokimab | Phase 2 data readout | Phase 2 | — | – | – | – |
2026-06-30 | sonelokimab | Phase 2 data readout | Phase 2 | — | – | – | – |
2026-06-30 | sonelokimab | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
C44
Pipeline Score $364M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.3x
rNPV / MCap Top 68%
Micro Cap (rank 293 of 913)
Percentile RankMoonLake Immunotherapeutics carries a moderate pipeline score (44/100), with $910M risk-adjusted pipeline value, led by Sonelokimab in Arthritis, Psoriatic (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sonelokimab Small molecule | Hidradenitis Suppurativa | Phase 3 | NCT06768671 | 58% | $910M | ACTIVE NOT_RECRUITING | 1,944 | SLOW | D (24) | Sep 28, 2026 | LOW_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
sonelokimab Fast Track | hidradenitis suppurativa | Phase 3 | 2026-06-21 | Hi SCR75: 67.2%; Hi SCR100: 33.1%; IHS4 100: 26.0%; mean Hi SQOL difference: -15.0; n: 396 Read More | MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 Read More | |
sonelokimab Fast Track | hidradenitis suppurativa | Phase 3 | 2026-06-21 | Hi SCR75: 67.2%; Hi SCR100: 33.1%; IHS4 100: 26.0%; mean Hi SQOL difference: -15.0; n: 396 Read More | MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 Read More | |
sonelokimab Fast Track | hidradenitis suppurativa | Phase 3 | 2026-06-21 | Hi SCR75: 67.2%; Hi SCR100: 33.1%; IHS4 100: 26.0%; mean Hi SQOL difference: -15.0; n: 396 Read More | MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MLTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MLTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MLTX▼ -5.7%on this news
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
MoonLake Immunotherapeutics has announced the pricing of an upsized public offering of 9 million Class A ordinary shares at $20 each, aiming to raise approximately $200 million. The proceeds will support the development and commercialization of sonelokimab, a treatment for inflammatory diseases. The offering is expected to close on June 25, 2026, pending customary conditions.
Read more →MLTXMoonLake Immunotherapeutics Announces Proposed Public Offering
MoonLake Immunotherapeutics has announced a proposed public offering of $150 million in Class A ordinary shares, with an additional $22.5 million option for underwriters. The funds will support the development and commercialization of sonelokimab, targeting inflammatory diseases. The offering is contingent on market conditions and is detailed in a prospectus filed with the SEC.
Read more →MLTX▲ +15.4%on this newsshared move
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
MoonLake Immunotherapeutics announced promising Week 52 results from its Phase 3 VELA trials for sonelokimab in treating moderate-to-severe hidradenitis suppurativa. The data showed a high percentage of patients achieving significant clinical responses and improvements in quality of life. The company plans to submit a Biologics License Application by September 2026 and will host an Investor Day on June 22, 2026, to discuss these findings.
Read more →MLTX▲ +10.4%on this news
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
MoonLake Immunotherapeutics announced a positive outcome from its final pre-BLA meeting with the FDA regarding sonelokimab for hidradenitis suppurativa. The FDA accepted MIRA trial data for effectiveness and agreed on the inclusion of VELA-TEEN trial data for adolescents. The BLA submission is planned for September 2026, with a potential commercial launch in late 2027.
Read more →MLTXMoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
MoonLake Immunotherapeutics announced positive Week 40 results from its Phase 3 VELA trials of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS). The trials demonstrated that 62% of patients achieved a HiSCR75 response, indicating significant clinical improvement. The data will be presented at the 2026 AAD Annual Meeting, reinforcing the potential of sonelokimab in addressing unmet needs in HS treatment.
Read more →MLTXMoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (
MoonLake Immunotherapeutics announced positive topline results from its Phase 2 clinical trial of sonelokimab in patients with axial spondyloarthritis. The trial demonstrated that 81% of participants achieved a significant improvement according to the ASAS40 response criteria at Week 12. The results indicate that sonelokimab has a rapid onset of action and effectively addresses inflammation in affected tissues. Additionally, the company's financial results from 2025 show sufficient funds to cover operations until mid-2027, supporting further developments in their pipeline that includes trials for other inflammatory diseases.
Read more →MLTXMoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
MoonLake Immunotherapeutics has received FDA Fast Track designation for sonelokimab to treat moderate-to-severe palmoplantar pustulosis (PPP). This designation aims to expedite the drug's development and review process, reflecting the serious nature of PPP and the lack of approved treatments. The company will also hold an Investor Day on February 23, 2026, to provide updates on various clinical programs.
Read more →MLTX▲ +27%on this news· ran to +64% by day 1
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulator
MoonLake Immunotherapeutics announced a positive outcome from its Type B meeting with the U.S. FDA, indicating that it can submit a Biologics License Application (BLA) for sonelokimab (SLK) without additional clinical trials. The FDA recognized the substantial evidence of effectiveness based on results from the VELA and MIRA trials for the treatment of hidradenitis suppurativa (HS). The meeting provided clarity for MoonLake's regulatory pathway and potential for further development of SLK for additional indications. An Investor Day is planned to discuss these outcomes and present new clinical data.
Read more →MLTXMOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm
A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors about its drug candidate, sonelokimab. The suit claims that the company falsely promoted sonelokimab as superior to rival products while omitting critical information regarding its efficacy. Following disappointing Phase 3 trial results, which revealed sonelokimab did not outperform BIMZELX, MoonLake's stock plummeted by nearly 90%. Investors who acquired stock during the specified period are urged to seek legal guidance regarding their rights.
Read more →MLTXMOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th
Bragar Eagel & Squire, P.C. is informing investors about a class action lawsuit against MoonLake Immunotherapeutics (MLTX) due to allegations of misleading statements about its drug candidate, sonelokimab. The lawsuit claims that MoonLake falsely promoted sonelokimab's clinical advantages while withholding information about its comparable efficacy to UCB's BIMZELX. Following the disappointing Phase 3 trial results, MoonLake's stock plummeted nearly 90%, leading to significant investor losses. Investors are encouraged to reach out to the law firm by December 15, 2025, for assistance with their legal rights.
Read more →MLTX▲ +5.1%on this newsshared move
MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MLTX
MoonLake Immunotherapeutics is embroiled in a class action securities lawsuit filed by Levi & Korsinsky, LLP. The lawsuit targets investors who experienced losses between March 10, 2024, and September 29, 2025, alleging that the company made misleading statements regarding its drug candidate SLK. Specific claims include that SLK's purported advantages over BIMZELX were unfounded and lacked a reasonable basis. Affected investors are urged to act promptly to request lead plaintiff status or to participate in the class action at no cost.
Read more →MLTXMOONLAKE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm
A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) in the U.S. District Court for the Southern District of New York, concerning allegations of misleading investors about the efficacy of its drug candidate, sonelokimab. During the announced Phase 3 trials, sonelokimab reportedly did not match the efficacy of UCB's BIMZELX. Following this announcement, the stock plummeted nearly 90%, resulting in significant financial losses for investors. Investors have until December 15, 2025, to seek lead plaintiff status in the lawsuit.
Read more →MLTXMOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline
A class action lawsuit has been initiated against MoonLake Immunotherapeutics due to alleged violations of the Securities Exchange Act of 1934. The complaint accuses the company of making misleading statements about its drug candidate, sonelokimab, particularly positioning it as superior to competing monoclonal antibodies. Investors who acquired shares between March 10, 2024, and September 29, 2025, may be eligible to participate in the action, with a deadline for lead plaintiffs set for December 15, 2025.
Read more →MLTXMoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
MoonLake Immunotherapeutics is embroiled in a class action lawsuit which alleges violations of securities laws due to misleading statements regarding its drug sonelokimab. The lawsuit highlights that the company claimed its drug outperformed competitors without backing those claims with proven advantages. Following the disastrous results from a Phase 3 trial, the credibility of the company’s public statements has come under scrutiny. Shareholders affected by the alleged misinformation are encouraged to contact the DJS Law Group for participation in the legal proceedings.
Read more →MLTXMoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money
MoonLake Immunotherapeutics is currently dealing with a lawsuit alleging securities fraud, filed by investors concerned about the company’s claims regarding its investigational therapy for hidradenitis suppurativa. The lawsuit comes on the heels of disappointing results from the Phase 3 VELA trials for sonelokimab, which failed to meet primary endpoints, thus threatening its chances for regulatory approval. The stock experienced a drastic drop from $61.99 to $6.24 in just a few days post-announcement, leading to investor losses and prompting calls for legal action.
Read more →MLTX▲ +6.6%on this news· ran to +20% by day 3shared move
MoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – MLTX
MoonLake Immunotherapeutics is being sued for securities law violations as a class action lawsuit pertains to misleading claims about its drug candidate SLK. The allegations state that the company failed to properly disclose the lack of clinical superiority of SLK over traditional monoclonal treatments. Shareholders who purchased stock during the specified class period are encouraged to participate in the lawsuit, with a registration deadline looming.
Read more →MLTXMoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights – MLTX
A class action securities lawsuit has been filed against MoonLake Immunotherapeutics alleging fraud. The lawsuit aims to recover losses for investors who were affected by false statements made about the company's drug candidate SLK during the period from March 10, 2024, to September 29, 2025. The complaint claims that the company misrepresented the drug's clinical benefits compared to its competitor BIMZELX. Affected investors have until December 15, 2025, to request lead plaintiff status in the lawsuit.
Read more →MLTXMoonLake Immunotherapeutics’ (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman
MoonLake Immunotherapeutics (MLTX) faces a class action lawsuit following a dramatic 90% drop in stock price attributed to disappointing results from a Phase 3 trial for its sole drug candidate, sonelokimab. The firm, Hagens Berman, alleges that MoonLake misrepresented SLK's clinical efficacy and advantages over competitors, which may have led to inflated stock prices. The trial data revealed that SLK did not perform as claimed, failing to meet its primary endpoints and showing lower efficacy than the competitor drug, BIMZELX. The lawsuit highlights concerns over potential securities fraud stemming from these alleged misrepresentations.
Read more →MLTXMoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
MoonLake Immunotherapeutics (MLTX) is facing a securities class action due to disappointing Phase 3 trial results for sonelokimab (SLK), its sole drug candidate for treating hidradenitis suppurativa. Following the announcement, shares dropped by 90%, prompting Hagens Berman to investigate whether the company misled investors regarding SLK's efficacy and design. Allegations include false statements about the advantages of SLK over a competing treatment, BIMZELX. The firm is urging affected investors to come forward and participate in the investigation.
Read more →MLTXMOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline
Bernstein Liebhard LLP has issued a reminder to investors of MoonLake Immunotherapeutics (NASDAQ: MLTX) regarding an impending deadline related to a securities fraud class action lawsuit. The lawsuit concerns allegations of misrepresentation about the company's drug candidate, sonelokimab, which was claimed to be superior to competing monoclonal antibodies. Investors who purchased shares between March 10, 2024, and September 29, 2025, are urged to take action if they wish to serve as lead plaintiffs in the case. The deadline for filing is December 15, 2025.
Read more →MLTXMoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate – Hagens Berman
MoonLake Immunotherapeutics is facing a securities class action following the release of disappointing Phase 3 trial results for its only drug candidate, sonelokimab (SLK), which resulted in a 90% drop in share price. The firm Hagens Berman is investigating claims that MoonLake misled investors regarding SLK’s trial efficacy and design. The lawsuit points to false statements made by the company about SLK's advantages over a competitor's product, raising concerns over potential investor deception. The investigation is ongoing as stakeholders look to address significant financial losses.
Read more →MLTXMoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
MoonLake Immunotherapeutics has announced the pricing of an underwritten offering of 7,142,857 Class A ordinary shares at $10.50 each, aiming to raise approximately $75 million. The proceeds will support the development of sonelokimab and general corporate purposes. The offering is expected to close on November 6, 2025, pending customary closing conditions.
Read more →MLTXMoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
MoonLake Immunotherapeutics reported its Q3 2025 financial results, highlighting a robust cash position of $380.5 million. The company shared promising data from its clinical trials of sonelokimab, particularly in the Phase 2 LEDA trial for palmoplantar pustulosis, showing significant clinical benefits. A Phase 3 trial is expected to commence in Q3 2026, with an FDA meeting scheduled for December 2025 to discuss the BLA submission.
Read more →MLTXMoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before December 15, 2025 to Discuss Your Rights – MLTX
MoonLake Immunotherapeutics is facing a securities fraud class action lawsuit as alleged by The Gross Law Firm. The lawsuit claims that the company issued misleading statements regarding its drug candidate SLK, which is purported to be superior to BIMZELX. Specific allegations include that SLK's structure does not provide the claimed clinical benefits and that the company lacked a reasonable basis for its positive assertions. Shareholders affected by these statements are urged to register for participation in the case before the lead plaintiff deadline on December 15, 2025.
Read more →MLTXMoonLake Immunotherapeutics Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights – MLTX
MoonLake Immunotherapeutics (MLTX) has been hit with a class action securities lawsuit alleging securities fraud, affecting investors between March 10, 2024, and September 29, 2025. The complaint claims that MoonLake made misleading statements regarding its drug candidate SLK, suggesting it would provide superiority over traditional monoclonal antibodies, which has been challenged by the lawsuit. Investors have until December 15, 2025, to participate in the legal process and may recover losses without upfront costs.
Read more →MLTX▲ +5.8%on this newsshared move
MoonLake Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against MLTX
MoonLake Immunotherapeutics is facing a class action lawsuit following its poor Phase 3 trial results for drug candidate SLK, which failed to show competitive efficacy against BIMZELX. Stockholders are encouraged to participate in the action due to alleged misrepresentations regarding the drug's clinical benefits. The stock price collapsed by 89.9% after the disappointing results were announced, leading to significant losses for investors. Robbins LLP is spearheading this class action and invites affected shareholders to seek further information.
Read more →MLTX▼ -5.2%on this newsshared move
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) INVESTOR ALERT Investors With Large Losses in MoonLake Immunotherapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights
A shareholder has initiated a securities class action lawsuit against MoonLake Immunotherapeutics, alleging that the company misrepresented its drug candidate, sonelokimab. This suit concerns investors who purchased stock between March 10, 2024, and September 29, 2025. The lawsuit raises serious questions about the company's practices and could result in substantial financial losses for shareholders. Investors have until December 15, 2025, to file papers if they wish to serve as lead plaintiffs in the case.
Read more →MLTXMoonLake Immunotherapeutics (MLTX) Investors with Substantial Losses Have Opportunity to Lead the MoonLake Class Action Lawsuit -- RGRD LLP
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against MoonLake Immunotherapeutics, focusing on alleged violations of the Securities Exchange Act. The lawsuit represents shareholders who suffered significant losses after the company reported discouraging Phase 3 trial results for its sole drug candidate, sonelokimab (SLK). It is claimed that the executives made misleading statements about SLK's efficacy compared to an existing treatment, BIMZELX. Following the announcement, MoonLake's stock price experienced a drastic decline of nearly 90%. Interested investors are invited to join the lawsuit before the December 15, 2025 deadline for lead plaintiff motions.
Read more →MLTXMOONLAKE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announced a class action lawsuit against MoonLake Immunotherapeutics, focusing on alleged misrepresentation of its drug candidate, sonelokimab. Investors who bought shares between March 10, 2024, and September 29, 2025, are being encouraged to contact the firm. The complaint claims that MoonLake failed to disclose the lack of proven superiority of sonelokimab over competing drugs, leading to substantial losses for investors after Phase 3 results revealed disappointing efficacy. The stock plummeted nearly 90% following these revelations.
Read more →MLTXMOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & Squire, P.C. Urges Investors in MoonLake to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders
Bragar Eagel & Squire, P.C. is investigating potential claims against MoonLake Immunotherapeutics (MLTX) on behalf of stockholders following a significant drop in stock value. On September 29, 2025, the company disclosed in an SEC filing that its VELA-2 trial did not achieve statistical significance due to unforeseen events in the placebo group, leading to an 89.9% decrease in stock price. The law firm is encouraging investors who suffered losses to contact them to discuss their legal options and rights.
Read more →MLTXMoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman
MoonLake Immunotherapeutics (MLTX) reported disappointing results from its Phase 3 VELA-2 trial for sonelokimab, leading to a 90% drop in share prices. The trial failed to achieve statistical significance due to higher-than-expected placebo outcomes. In light of these results, Hagens Berman has launched an investigation into whether the company misled investors regarding the trial's design and efficacy. This situation has resulted in substantial financial losses for investors who believed in the drug's potential as the 'gold standard' treatment for hidradenitis suppurativa.
Read more →MLTX▲ +7.2%on this news· ran to +18% by day 3shared move
MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating MoonLake Immunotherapeutics for potential violations of federal securities laws following a significant decline in share value. On September 29, 2025, the company reported that its VELA-2 trial had failed to achieve statistical significance, resulting in an 89.9% drop in stock price. The law firm invites affected investors to discuss their legal options as the situation develops, underlining serious concerns regarding the company's business practices.
Read more →MLTXMoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm’s Investigation
Block & Leviton is launching an investigation into MoonLake Immunotherapeutics for potential securities law violations after the company's shares plummeted over 85%. This decline followed disappointing results from its Phase 3 VELA trials, which failed to meet key endpoints. Investors who lost money can contact Block & Leviton to explore options for recovering their losses. The firm has a strong reputation for handling securities class action cases and aims to pursue significant recoveries for affected investors.
Read more →MLTX▲ +5.7%on this news· ran to +31% by day 3shared move
MOONLAKE ALERT: Bragar Eagel & Squire, P.C. Announces Investigation into MoonLake Immunotherapeutics on Behalf of MoonLake Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has launched an investigation into MoonLake Immunotherapeutics following significant stock losses experienced by investors. This investigation is prompted by the company's recent announcement regarding its VELA-2 trial, which failed to achieve statistical significance. On September 29, 2025, the stock dropped 89.9%, raising questions about potential violations of federal securities laws and business practices. Investors who have incurred losses are encouraged to reach out to the firm for more information on their legal options.
Read more →MLTX▼ -89.9%on this newsshared move
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
MoonLake Immunotherapeutics reported positive week 16 results from its Phase 3 VELA trials for sonelokimab in treating moderate-to-severe hidradenitis suppurativa. The trials demonstrated statistically significant improvements in key endpoints, including HiSCR75 response rates and patient-reported outcomes. Despite a higher-than-expected placebo response in one trial, the overall safety profile remains favorable. The company plans to discuss these results with regulators as they move towards a potential Biologics License Application.
Read more →MLTXMoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics reported strong financial results for Q2 2025, highlighting a cash position of $425.1 million and an earlier-than-expected interim readout from the Phase 2 LEDA trial. The company narrowed its guidance for the Phase 3 VELA program's primary endpoint readout to September. Upcoming milestones include data presentation at a key scientific congress in Q4 2025.
Read more →MLTXMoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
Read more →MLTXMoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
MoonLake Immunotherapeutics will host a virtual Capital Markets Day on April 29, 2025, to discuss recent financial and clinical advancements. The event will feature insights from key executives and cover the company's non-dilutive financing agreement, updates on the VELA program, and interim results from the LEDA study. A Q&A session will follow the presentations.
Read more →MLTXMoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
MoonLake Immunotherapeutics announced a significant agreement with Hercules Capital for up to $500 million in non-dilutive financing. This funding will support the advancement of sonelokimab, a novel treatment for inflammatory diseases. The company plans to provide important clinical updates during a Capital Markets Update on April 29, 2025, including pivotal data readouts for ongoing trials.
Read more →MLTXMoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Read more →MLTXMoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
MoonLake Immunotherapeutics has initiated three new clinical trials for sonelokimab, targeting adolescent hidradenitis suppurativa, palmoplantar pustulosis, and axial spondyloarthritis. This expansion increases the total number of clinical trials to ten, with plans to enroll over 3,000 patients. The trials aim to address significant unmet medical needs in dermatology and rheumatology.
Read more →MLTXMoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
Read more →MLTXMoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
Read more →MLTXMoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
Read more →MLTXMoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
Read more →MLTXMoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody sonelokimab in Psoriatic Arthritis Builds upon the positive regulatory feedback re
MoonLake Immunotherapeutics received encouraging feedback from both the FDA and EMA regarding its Phase 3 program for sonelokimab in treating psoriatic arthritis. The program, named IZAR, is set to involve approximately 1,500 patients across two randomized trials, assessing the efficacy and safety of the drug over one year. These positive regulatory outcomes provide a clear development pathway for the company and build upon previous successes in related conditions. The readout of the primary endpoint is anticipated by late 2026, marking a significant milestone in the treatment of this condition.
Read more →MLTXMoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
Read more →MLTXMoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
Read more →MLTXMoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
MoonLake Immunotherapeutics has announced a three-year partnership with Komodo Health to enhance research and treatment for inflammatory skin and joint conditions, particularly hidradenitis suppurativa and psoriatic arthritis. The collaboration will leverage Komodo's technology and real-world data to inform clinical operations and accelerate the development of MoonLake's nanobody-based therapy. The data provided by Komodo is expected to offer insights into market dynamics and patient journeys, supporting MoonLake's commercialization efforts. This partnership reflects a significant step towards fulfilling unmet medical needs in these conditions.
Read more →MLTXMoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day Positive 24-week data from the ARGO trial of sonelokimab
MoonLake Immunotherapeutics announced positive results from the 24-week ARGO trial of sonelokimab in patients with active psoriatic arthritis (PsA). The treatment demonstrated significant improvements, with over 60% achieving ACR 50 and 40% achieving ACR 70. Furthermore, the data indicated high response rates in skin symptoms, exceeding those of the reference drug adalimumab. The company plans to initiate Phase 3 trials for sonelokimab in both PsA and hidradenitis suppurativa later this year, alongside expansions into other inflammatory diseases.
Read more →MLTXMoonLake Immunotherapeutics to present MIRA trial data of Nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics announced that it will present 24-week data from the MIRA trial of its Nanobody sonelokimab for hidradenitis suppurativa at the AAD Annual Meeting on March 10, 2024. The trial aims to demonstrate the efficacy and safety of sonelokimab in treating moderate to severe cases of this chronic skin condition. This presentation follows earlier positive results from the trial, indicating the potential of sonelokimab as a significant therapeutic option. The company continues to focus on developing innovative treatments for inflammatory diseases.
Read more →MLTX▼ -15.1%on this newsshared move
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
Read more →MLTXMoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody sonelokimab (SLK) in Hidradenitis Suppurativa (HS) Clarified path for HS Phase 3 pr
MoonLake Immunotherapeutics has announced favorable feedback from the FDA and EMA regarding the regulatory path for its Phase 3 program for sonelokimab (SLK) in treating hidradenitis suppurativa (HS). The Phase 3 trial, named VELA, will enroll 800 patients and aims to gather data to support a Biologics License Application. This supportive feedback highlights the company's strategic approach and enhances the clarity of its clinical development program. The primary endpoint results are expected in mid-2025, marking a significant step in addressing an unmet need in the treatment of HS.
Read more →MLTXMoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
Read more →MLTX▼ -29.1%on this news
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
Read more →MLTX▼ -29.1%on this news
Document Exh ibit 99.1 MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis First placebo-controlled randomized trial in active psoriatic arthritis (PsA) u
MoonLake Immunotherapeutics has reported positive Phase 2 results for its Nanobody sonelokimab in treating active psoriatic arthritis (PsA). The ARGO trial demonstrated that up to 47% of patients achieved an ACR50 response by week 12, exceeding placebo outcomes. Additionally, all key secondary endpoints were successfully met, including impressive responses in skin clearance. The trial noted a low discontinuation rate and consistent safety results, positioning sonelokimab as a potential leading therapy for PsA as the company prepares for Phase 3 trials.
Read more →MLTX▲ +10.7%on this news
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativ
MoonLake Immunotherapeutics announced positive results from its 24-week Phase 2 MIRA clinical trial for sonelokimab, a Nanobody treatment for hidradenitis suppurativa (HS). The trial showed enhanced HiSCR75 response rates and improvements in various clinically relevant outcomes among patients with moderate-to-severe HS. Notably, 57% of patients receiving the 120mg dose achieved a HiSCR75 response, reflecting effective management of HS symptoms. The favorable safety profile and significant patient-reported outcomes reinforce the potential of sonelokimab as a new treatment option in this challenging to treat condition.
Read more →MLTX▼ -7.1%on this newsshared move
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
Read more →MLTXMoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
MoonLake Immunotherapeutics AG will host a Capital Markets Day on September 11, 2023, to discuss the evolving psoriatic arthritis market and upcoming trial results. The event will include updates on the Phase 2 ARGO trial and the 24-week data from the MIRA trial, both of which are crucial as the company develops sonelokimab for inflammatory diseases. An external expert, Dr. Joseph F. Merola, will also present at the event, followed by a Q&A session for attendees.
Read more →MLTXMoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS), suggest
MoonLake Immunotherapeutics reported its financial results for the second quarter of 2023, showcasing significant progress in its clinical development of sonelokimab. Notably, the Phase 2 MIRA trial for hidradenitis suppurativa achieved a landmark milestone with positive results, indicating strong efficacy in treatment. The company has also successfully enrolled patients more rapidly than expected in its ongoing clinical trials for both hidradenitis suppurativa and psoriatic arthritis. With substantial fundraising efforts complete, MoonLake is now gearing up for further advancements into Phase 3 programs for sonelokimab, aiming to address critical unmet needs in inflammatory diseases.
Read more →MLTXMoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
MoonLake Immunotherapeutics has completed patient randomization for its Phase 2 ARGO trial in active psoriatic arthritis ahead of schedule, successfully enrolling 200 patients. The expected top-line results for 12 weeks are set to be announced in early November 2023, in alignment with the American College of Rheumatology Conference. The company will also hold a Capital Markets Day to discuss market expectations and updates from this trial and the MIRA trial for hidradenitis suppurativa. This marks the second trial where MoonLake has seen faster-than-expected recruitment, reflecting strong interest in its innovative therapy sonelokimab.
Read more →MLTXMoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
Read more →MLTX▲ +77.6%on this news· ran to +100% by day 1shared move
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
MoonLake Immunotherapeutics has announced a proposed underwritten public offering of $250 million in its Class A ordinary shares. The offering is expected to support the advancement of its investigational therapy, Sonelokimab, aimed at treating inflammatory diseases. The company also allows for the option of pre-funded warrants to certain investors. However, the completion of the offering is contingent on market conditions, introducing a level of uncertainty related to size and terms.
Read more →MLTX▲ +77.6%on this news· ran to +100% by day 1shared move
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody sonelokimab in hidradenitis suppurativa First placebo-controlled randomized trial in HS to report positive topline result
MoonLake Immunotherapeutics announced positive Phase 2 results for sonelokimab in hidradenitis suppurativa, marking a milestone in clinical development with its primary endpoint HiSCR75 significantly met. This trial was notable as it was the first randomized, placebo-controlled study to use HiSCR75, demonstrating promising efficacy compared to prior therapies. The safety profile of sonelokimab was consistent with previous reports, indicating no new safety concerns. The trial results highlight the potential of sonelokimab as a treatment option for patients with this chronic condition.
Read more →MLTXMoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
Read more →MLTX▲ +7.5%on this news· ran to +28% by day 3
MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply
MoonLake Immunotherapeutics has partnered with SHL Medical to develop an autoinjector for its investigational Nanobody sonelokimab, which is being explored for inflammatory diseases. This collaboration is expected to leverage SHL's expertise in drug delivery systems to enhance the clinical and commercial supply of sonelokimab. The nanobody has shown promising results in previous clinical trials, including rapid skin clearance in psoriasis patients. With ongoing studies for other conditions like hidradenitis suppurativa and psoriatic arthritis, the partnership aims to provide a beneficial treatment option for patients.
Read more →MLTXMoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
Read more →MLTX▼ -7.9%on this news
MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics reported its financial results and business updates for Q4 and year-end 2022, underscoring a strong financial position with $72.1 million in cash. The company announced successful patient enrollment in global Phase 2 trials for sonelokimab in hidradenitis suppurativa and psoriatic arthritis, with top-line results anticipated for mid to late 2023. Recent clinical data further bolster its competitive edge, highlighting sonelokimab's novel dual inhibition mechanism. However, the company also reported a net loss of $64.5 million for the year, raising concerns about financial sustainability as expenses increase.
Read more →MLTXMoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics has successfully completed patient enrollment and randomization for its Phase 2 trial of sonelokimab in moderate-to-severe hidradenitis suppurativa ahead of schedule. The trial, which aims to enroll 210 patients, is notable for using HiSCR75 as its primary endpoint, a higher measure of clinical response. Results are expected by mid-2023, marking significant advancements in assessing the efficacy of this novel Nanobody. The study aims to evaluate various doses of sonelokimab against placebo and adalimumab, focusing on a debilitating chronic skin condition.
Read more →MLTXMoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
Read more →MLTXMoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
Read more →MLTXMoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
Read more →MLTX▲ +13.3%on this news
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
Read more →MLTXMoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
Read more →MLTXMoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab
Read more →MLTXMoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp. MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology ther
MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp. MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company elevating care with innovative immunology therapeutics, will be listed on Nasdaq under the ticker "MLT
Read more →MLTXMoonLake ImmunotheraPeutics AG and Helix Acquisition Corp. Announce BUSINESS COMBINATION Agreement to Create PUBLICLY LISTED BIOTECHNOLOGY COMPANY ADVANCing tri-specific nanobody sonelokimab - Total proceeds expected to
MoonLake ImmunotheraPeutics AG and Helix Acquisition Corp. Announce BUSINESS COMBINATION Agreement to Create PUBLICLY LISTED BIOTECHNOLOGY COMPANY ADVANCing tri-specific nanobody sonelokimab Switzerland and Boston, MA - Oct. 4, 2021 - MoonLake Immunotherapeutics AG, a clinica
Read more →MLTXHELIX ACQUISITION CORP. Index to Financial Statement Page Report of Independent Registered Public Accounting Firm F-2 Financial Statement: Balance Sheet as of
to Financial Statement Page Report of Independent Registered Public Accounting Firm F-2 Financial Statement: Balance Sheet as of October 22, 2020 F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC To the Shareholders and the Board of Directors
Read more →MLTXHelix Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering Boston, MA
Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering MA - Oct 19, 2020 - Helix Acquisition Corp. (the "Company") announced today that it priced its initial public offering of 10,000,000 Class A ordinary shares at $10.00 per share. The shares will be liste
Read more →Competitive Position
How MLTX ranks across every disease it competes inCompetitive Position is a premium feature
See how MLTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial